Add BrightSurf on Google Email

Global burden of disease analysis finds China carries a larger absolute burden while the United States has higher age-standardized rates

China has more prevalent cases of pancreatic cancer (103,000 vs. 66,000), but lower age-standardized rates, compared to the US. The US has higher age-standardized rates of incidence, mortality, and disability-adjusted life years (DALYs), attributed to high fasting plasma glucose being the leading risk factor

SourceChinese Medical Journals Publishing House Co., Ltd.·JournalJournal of Pancreatology·TypeData/statistical analysis·DateNov 13, 2026

Scientists identify inhibition of a specific enzyme as a promising target to treat pancreatic cancer

Researchers have identified complement factor B as a promising target for pancreatic cancer treatment. Inhibiting this enzyme suppresses cancer growth, induces cellular senescence, and remodels the tumor immune microenvironment. The combination of CFB inhibition with chemotherapy and immunotherapy showed the greatest tumor suppression.

SourceElsevier·JournalAmerican Journal Of Pathology·TypeExperimental study·DateNov 9, 2026

Making tumors more responsive to immunotherapy

Researchers have discovered how reprogrammed cancer cells can promote the formation of immune cells clusters that help coordinate the immune response, leading to better treatment outcomes for patients. The study's findings suggest that cell reprogramming could become a way to make tumors more responsive to immunotherapy.

SourceLund University·JournalImmunity·TypeExperimental study·DateNov 6, 2026

Continuously evolving cells help pancreatic cancer evade treatment and spread

Researchers analyzed nearly half a million cells from dozens of patients' tumors to understand how pancreatic cancer cells continuously evolve over time. The study found that specific genetic changes, such as increased activity of the MYC gene, enable cancer cells to resist therapy and spread rapidly.

SourceNYU Langone Health / NYU Grossman School of Medicine·JournalNature Genetics·TypeExperimental study·DateOct 13, 2026

New device targets nerve signals to treat cancer-related wasting, moving to first human trial

A new device has been approved for a first human trial to treat cancer-related wasting, a severe and progressive syndrome affecting many patients with advanced cancer. The device, OnVagus, delivers noninvasive electrical stimulation to modulate the vagus nerve, aiming to preserve strength and quality of life during treatment.

SourceTerasaki Institute for Biomedical Innovation·TypeRandomized controlled/clinical trial·DateOct 7, 2026

Pancreatic cancer burden rises in both China and the US, but patterns diverge

A new study finds that high fasting glucose has surpassed tobacco use as the leading risk factor for pancreatic cancer in the US, while China faces a dual metabolic-tobacco burden. China recorded more absolute cases, but lower age-standardized rates, with a peak burden at ages 60-74.

SourceChinese Medical Journals Publishing House Co., Ltd.·JournalJournal of Pancreatology·TypeData/statistical analysis·DateSep 30, 2026

Regulator-mandated study finds no link between semaglutide use and pancreatic cancer using nationwide registry data from Denmark, Sweden and Norway

A regulator-mandated study found no link between semaglutide use and pancreatic cancer using nationwide registry data from Denmark, Sweden, and Norway. The study, funded by Novo, included over 97,000 semaglutide users and compared them to users of other non-incretin antidiabetic drugs.

China reports real-world surgical outcomes for 6,297 pancreatic cancer patients

A Chinese registry report presents real-world perioperative and survival outcomes for surgically treated pancreatic cancer patients, achieving high overall survival rates and encouraging surgical safety metrics. The study emphasizes the need for national-level benchmarks and standardized clinical protocols for pancreatic surgery in China.

SourceChinese Medical Journals Publishing House Co., Ltd.·JournalJournal of Pancreatology·TypeData/statistical analysis·DateSep 25, 2026

The dawn of RAS-targeted therapy: a landmark breakthrough of daraxonrasib in pancreatic cancer

Daraxonrasib, a novel RAS-targeted therapy, has been approved for adults with metastatic pancreatic adenocarcinoma. Clinical trials have shown a median overall survival of 13.2 months and nearly three times the objective response rate compared to chemotherapy. The medication targets KRAS, NRAS, and HRAS mutations, covering over 90% of ...

SourceEditorial Office and Clinical Cancer Bulletin·JournalClinical Cancer Bulletin·TypeCommentary/editorial·DateSep 16, 2026

mRNA immunotherapy developed by UMass Chan scientists eliminates pancreatic tumors in mice

Researchers have developed an mRNA immunotherapy that eliminates pancreatic tumors in mice, achieving complete tumor responses and long-term disease-free periods. The treatment uses a cocktail of immune cytokine and tumor-associated antigen mRNAs, showing promise as a potential transformative treatment for pancreatic cancer.

SourceUMass Chan Medical School·JournalNature Communications·TypeExperimental study·DateAug 25, 2026

AGR2-high cells drive a FOXM1-mediated pro-malignancy program in non-functional pancreatic neuroendocrine tumors (NF-PanNETs) and informatively predict patient outcomes

Researchers identify AGR2 as a prognostic marker for NF-PanNETs, while FOXM1 is found to promote malignancy and proliferation. AGR2-high cells exhibit malignant features, including increased proliferative activity and metastasis-like signatures.

SourceScience China Press·JournalScience Bulletin·TypeExperimental study·DateAug 13, 2026

Researchers uncover pathway for antisense therapy delivery

Scientists at Cancer Research UK Scotland Institute and University of Glasgow identify a new pathway for delivering antisense oligonucleotides (ASOs) into cells, enhancing the effectiveness of ASO-based therapy for pancreatic cancer and other diseases. The researchers found that ASOs enter cells via endocytosis and bind to specific rec...

SourceRockefeller University Press·JournalJournal of Cell Biology·TypeExperimental study·DateAug 11, 2026

Bugs as drugs: Engineered gut bacteria show promise against pancreatic cancer

Researchers at the University of Chicago report a promising new strategy using BifidoSumIL-2, an engineered bacterial strain, to deliver an immune-stimulating therapy directly into pancreatic tumors. The treatment selectively activates cancer-fighting T cells and slows tumor growth, even when combined with chemotherapy or radiotherapy.

SourceUniversity of Chicago Medical Center·JournalScience Advances·TypeExperimental study·DateJul 24, 2026

Fasting primes gut microbiome to improve intestinal recovery after radiation treatment

A new preclinical study has identified a gut bacterium, Akkermansia muciniphila, that helps prime intestinal stem cells for faster recovery after radiation treatment. Fasting increases the population of this bacterium, which produces a small molecule that changes histone tags to allow gene expression in intestinal cells.

SourceUniversity of Texas M. D. Anderson Cancer Center·JournalProceedings of the National Academy of Sciences·DateJul 9, 2026

Chinese consensus on early screening and surveillance for pancreatic cancer in high-risk individuals (2026 revision, Nanjing)

A multidisciplinary panel of experts recommends evidence-based screening and surveillance strategies for pancreatic cancer in high-risk populations, aiming to improve early diagnosis and survival. The guidelines specify starting ages, surveillance intervals, imaging modalities, surgical indications, and lifestyle modifications.

SourceXia & He Publishing Inc.·JournalCancer Screening and Prevention·DateJun 23, 2026

Inducing cell death in pancreatic cancer cells

A team of researchers has identified a previously unknown vulnerability in KRAS-mutated pancreatic cancer cells, making them susceptible to necroptosis. Blocking the tumor cells' defense mechanism by inhibiting caspase-8 leads to significant cell death and reduced tumor growth.

SourceUniversity of Cologne·JournalNature Communications·TypeExperimental study·DateJun 16, 2026

Experimental compounds trigger cancer cell death in KRAS-driven pancreatic cancer

Researchers investigated polyisoprenylated cysteinyl amide inhibitors (PCAIs) for their anticancer effects on pancreatic cancer cells with KRAS mutations. The compounds demonstrated strong activity against cell survival, migration, and invasion pathways. PCAI treatment caused hyperactivation of MAPK and PI3K/AKT pathways, leading to ox...

SourceImpact Journals LLC·JournalOncotarget·TypeNews article·DateJun 8, 2026

Weight loss treatments linked to lower risk of obesity-related cancers in people without diabetes

A study of over 229,000 obese adults without diabetes found that weight loss drugs, such as semaglutide and tirzepatide, were associated with a 41% decrease in the overall risk of developing obesity-related cancers. GLP-1 RAs also showed larger reductions in certain subgroups, including men and gynaecologic cancers.

SourceEuropean Society for Medical Oncology·JournalAnnals of Oncology·TypeObservational study·DateJun 7, 2026